Feasibility of 320-row multi-detector computed tomography angiography to assess bioabsorbable everolimus-eluting vascular scaffolds

Coronary computer tomographic angiography (CCTA) for screening intra-arterial vessel disease is gaining rapid clinical acceptance in recent years, but its use for such assessments in metal-stented vessel segments is very limited due to blooming artifacts introduced by the metal. However, vessel segments treated by the polymeric everolimus-eluting bioresorbable vascular scaffolds (Absorb) are readily monitored for intravascular disease over time with CCTA. The data on the accuracy of multi-detector computed tomography (MDCT) in patients treated with Absorb is still sparse. Results on 5 Japanese case studies from ABSORB EXTEND are presented here. Five patients were treated with Absorb, and follow-up angiography was conducted at 8 to 14 months as per routine site standard of practice. 320-row MDCT scan was performed within 1 month before the angiography. By MDCT, all Absorb-treated lesions were clearly evaluated and restenosis were not observed. Minimal diameter and % diameter stenosis were similar between MDCT and quantitative angiography (2.07 ± 0.13 vs. 2.03 ± 0.06 mm, P = 0.86, and 22.5 ± 5.0 vs. 21.5 ± 4.5 %, P = 0.88, respectively). MDCT appears to be feasible and useful for evaluating lumen patency and vessel disease in segments implanted with Absorb at follow-up.

• View at Publisher
• View at Scopus